Beam Therapeutics (BEAM) reported second quarter 2026 results that showed a wider net loss and higher loss per share, which has become a key focus for investors assessing the stock this week.
See our latest analysis for Beam Therapeutics.
Despite the wider quarterly loss, Beam Therapeutics has seen a sharp 1 day share price return of 9.42% and a 7 day share price return of 7.84%. However, the 30 day share price return is down 18.51% and the 90 day share price return is down 12.34%. At the same time, the year to date share price return is 4.46%, while the 1 year total shareholder return of 51.60% contrasts with a 5 year total shareholder return that is down 72.81%. This suggests recent momentum has improved after a difficult longer term period.
If Beam Therapeutics has put biotech on your radar, it could be useful to broaden your watchlist with other healthcare focused AI opportunities using the 41 healthcare AI stocks
Beam Therapeutics just reported a wider quarterly loss alongside a sharp short-term bounce in its share price. The science may be attracting fresh interest. Does the current valuation fairly reflect that balance between risk and potential reward?
Most Popular Narrative: 44.5% Undervalued
Beam Therapeutics closed at $28.35 while the most followed narrative pegs fair value at $51.07. This implies a sizeable gap that hinges on ambitious long term expectations.
The development of ESCAPE technology aims to expand the addressable patient population for gene editing by eliminating chemotherapy, which could significantly increase the market and, subsequently, revenue and margins.
Beam has nominated BEAM-103 and BEAM-104 for their ESCAPE program, which could bring transformative changes in transplant medicine by enabling non-genotoxic conditioning, leading to broader patient access and a potential increase in revenue.
Want to understand why this fair value sits well above today’s price? The narrative focuses on aggressive revenue expansion, margin uplift, and rich future earnings multiples. The full breakdown explains how those moving parts are expected to fit together.
Result: Fair Value of $51.07 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this upbeat Beam Therapeutics story still hinges on managing busulfan safety concerns and securing ongoing funding, so any setbacks there could quickly challenge the bullish case.
Find out about the key risks to this Beam Therapeutics narrative.
Another View On Beam Therapeutics Valuation
The fair value of $51.07 for Beam Therapeutics comes from long term earnings assumptions. A simpler cross check looks at the current P/S ratio of 18.1x versus a fair ratio of 1x. That gap is very wide, which could mean valuation risk if growth or margins fall short. Which signal do you put more weight on?
To see how this price stacks up against peers, including the wider US Biotechs industry at 10.5x P/S and a peer average of 22.6x, it helps to walk through the underlying numbers in detail. See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With Beam Therapeutics presenting both enthusiasm around its technology and concerns around its financial profile, now is a good time to review the full picture yourself and move quickly to shape your own stance using the 2 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Beam Therapeutics?
If Beam Therapeutics has sharpened your focus, now is the moment to widen your opportunity set and evaluate your portfolio with fresh, data backed ideas.
- Explore potential opportunities by scanning companies that combine quality fundamentals with attractive pricing using the 52 high quality undervalued stocks.
- Support a more defensive core by reviewing businesses that prioritize resilience and lower risk profiles through the 82 resilient stocks with low risk scores.
- Consider lesser known opportunities with strong fundamentals by checking the screener containing 18 high quality undiscovered gems before the wider market does.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com